SCHEMBL25321995

SCHEMBL25321995

C[C@H]1CC[C@H](c2ccc3c(cnn3C)c2)NC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1C Q14123 7/20 0.43
KDM1A O60341 3/20 0.38
PDE2A O00408 1/20 0.37
PDE5A O76074 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE7A Q13946 1/20 0.37
PDE10A Q9Y233 1/20 0.37
CREBBP Q92793 3/20 0.36
BRD4 O60885 2/20 0.36
CTNNB1 P35222 1/20 0.36
TCF7 P36402 1/20 0.36
DYRK3 O43781 2/20 0.35
CLK1 P49759 2/20 0.35
CLK3 P49761 2/20 0.35
DYRK1A Q13627 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25322455 0.84 SLC5A2 (0.37) KDM1APTGER3
SCHEMBL25324043 0.84 BRD4 (0.38) KDM1ACREBBPBRD4PTGER3
SCHEMBL25322453 0.84 SLC5A2 (0.37) KDM1APTGER3
SCHEMBL25324041 0.84 BRD4 (0.38) KDM1ACREBBPBRD4PTGER3
SCHEMBL25324241 0.82 SLC5A2 (0.36) KDM1APTGER3
SCHEMBL25321347 0.82 BRD4 (0.37) KDM1ACREBBPBRD4PTGER3
SCHEMBL29343727 0.81 KCNH2 (0.38)
SCHEMBL29081551 0.81 KCNH2 (0.38)
SCHEMBL15344928 0.77 PDE1C (0.44) PDE1CKDM1APDE2APDE5ACYP2C9
SCHEMBL29769081 0.75 PDE1C (0.48) PDE1CKDM1APDE2APDE5ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN PDE1C 4035/4885KDM1A 1016/4885PDE2A 1122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.